Printer Friendly

Arjuna Natural Extracts Ltd gets positive response letter from US FDA for high-potency turmeric extract BCM-95 Curcumin.

M2 PHARMA-August 3, 2017-Arjuna Natural Extracts Ltd gets positive response letter from US FDA for high-potency turmeric extract BCM-95 Curcumin


Botanical extracts company Arjuna Naturals Extracts Ltd said on Wednesday that it has received a 'No Questions' response letter " from the US Food and Drug Administration (FDA) for its high-potency turmeric extract BCM-95 Curcumin.

The company said the US FDA letter confirms the complete safety of BCM-95, positioning the formulation as an all-natural, clean and trusted brand of the curcumin antioxidant. BCM-95 is a proprietary combination of curcuminoids and essential oil of turmeric-ar-turmerone, ensuring a high level of bioavailability of curcumin.

According to the company, the BCM-95 has been extensively researched in 33 clinical studies by universities throughout the US, Japan, Australia, and India, backing its efficacy for multiple health indications. The formulation holds 13 international patents.

Additionally, BCM-95 was granted self-affirmed GRAS status (Generally Recognized as Safe) by an expert panel of scientists for use in medical foods at a dose of 500 mg, twice a day. The synergism of its components has been published in the journal, Scientific Reports, by Shusuke Toden, PhD, et alia, of Baylor University, Dallas, Texas.

In conjunction, BCM-95 is the registered trademark of Dolcas Biotech LLC, USA. Arjuna has full supervision of BCM-95's supply chain, from farm to finished supplement, to provide a pure, clean and safe product.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 3, 2017
Previous Article:MedEquities announces dividend of USD0.21 per share for Q2 2017.
Next Article:Haldex's board unanimously decides not to support Knorr-Bremse takeover offer.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters